---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-123481"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2023-12-05T23:59:59+00:00"
generated_at: "2026-06-07T17:40:49.707909+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Novavax reaches $47M settlement in principle to resolve securities class action

## Summary
- Company agreed to pay $47M into settlement fund; expects D&O insurance to fund it.
- Settlement resolves surviving claims about alleged false statements on vaccine manufacturing and regulatory approval.
- Class period: February 24, 2021 to October 19, 2021; court approval required.
- Settlement includes customary releases and a disclaimer of liability by Novavax and named executives.
- Previously, court dismissed some claims but allowed others to proceed; parties now seek to end litigation.

## SEC filing metadata
- accession: 0001104659-23-123481
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2023-12-05T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465923123481/0001104659-23-123481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465923123481/tm2332186d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-123481
- JSON: https://secwatch.observer/filing/0001104659-23-123481.json
- Plain text: https://secwatch.observer/filing/0001104659-23-123481.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.